ReviewJournal of clinical hypertension (Greenwich, Conn.)2006
Drug-induced metabolic syndrome.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.International urology and nephrology · 2018Pooled it
- Emerging Role of Myostatin Inhibitors in the Management of Glucagon-Like Peptide-1-Associated Sarcopenia and Metabolic Disorders.Journal of bone metabolism · 2025Article
- Metabolic Syndrome in Older Adults: Through the Lens of Institute for Healthcare Improvement's (IHI) 4Ms Framework and Social Determinants of Health.Life (Basel, Switzerland) · 2025Review
- High-density lipoprotein (HDL) as an indicator for alcohol use in a psychiatrically ill population.Alcohol and alcoholism (Oxford, Oxfordshire) · 2024Observational
- Quantifying Food Intake in Caenorhabditis elegans by Measuring Bacterial Clearance.Journal of visualized experiments : JoVE · 2024Article
- Association between metabolic syndrome and gastric cancer risk: results from the Health Examinees Study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023Article
- Valproate-Induced Metabolic Syndrome.Biomedicines · 2023Review
- Nuclear receptor 5A2 regulation of Agrp underlies olanzapine-induced hyperphagia.Molecular psychiatry · 2023Review
- Obesity and Its Multiple Clinical Implications between Inflammatory States and Gut Microbiotic Alterations.Diseases (Basel, Switzerland) · 2022Review
- Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain.Translational psychiatry · 2021Article
- Metabolic syndrome and its associated factors in Ethiopia: A systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2021Review
- Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain.Scientific reports · 2020Article
- Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain.Physiology & behavior · 2020Article
- Association of benzodiazepines, opioids and tricyclic antidepressants use and falls in trauma patients: Conditional effect of age.PloS one · 2020Article
- A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia.Nature communications · 2018Article
- Animal models of metabolic syndrome: a review.Nutrition & metabolism · 2016Review
- The skin function: a factor of anti-metabolic syndrome.Diabetology & metabolic syndrome · 2012Article
- A key role for the transporter OAT1 in systemic lipid metabolism.The Journal of biological chemistryArticle
- Secondary metabolic syndrome: the frequency of factors which may underlie the parameters of metabolic syndrome.Annals of Saudi medicineObservational
- Metabolic Syndrome and Skin: Interactions and Implications.Indian journal of dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The metabolic syndrome is a cluster of risk factors associated with an increased risk for cardiovascular disease and type 2 diabetes. Based on data from 1988 to 1994, it is estimated that 24% of adults in the United States meet the criteria for diagnosis of the metabolic syndrome. The use of certain medications may increase the risk of the metabolic syndrome by either promoting weight gain or altering lipid or glucose metabolism. Health providers should recognize and understand the risk associated with certain medications and appropriately monitor for changes related to the metabolic syndrome. Careful attention to drug choices should be paid in patients who are overweight or have other risk factors for diabetes or cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.